Company: CI
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001739940-25-000028
Chunk: 196

Company: Cigna Group
Filing Date: 2025-07-31
Form: 10-Q
Item: Part II, Item 12
Chunk 196
---
 changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.For the six months ended June 30, 2025, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. For the six months ended June 30, 2024, we determined our investment in VillageMD was impaired and recorded a $1.8 billion loss in Net investment gains (losses) in the Company's Consolidated Statements of Income. Observable price changes for equity securities with no readily determinable fair value were not material for the six months ended June 30, 2025 or June 30, 2024.

23

C.Fair Value Disclosures for Financial Instruments Not Carried at Fair Value

The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.Classification in Fair Value HierarchyJune 30, 2025December 31, 2024(In millions)Fair ValueCarrying ValueFair ValueCarrying ValueCommercial mortgage loansLevel 3$1,256 $1,311 $1,256 $1,351 Long-term debt, including current maturities, excluding finance leasesLevel 2$27,419 $29,503 $28,392 $31,008